PROCEPT BioRobotics Corporation

NasdaqGM PRCT

PROCEPT BioRobotics Corporation Price to Book Ratio (P/B) on January 14, 2025: 17.10

PROCEPT BioRobotics Corporation Price to Book Ratio (P/B) is 17.10 on January 14, 2025, a 55.37% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

PROCEPT BioRobotics Corporation 52-week high Price to Book Ratio (P/B) is 21.05 on December 04, 2024, which is 23.08% above the current Price to Book Ratio (P/B).
PROCEPT BioRobotics Corporation 52-week low Price to Book Ratio (P/B) is 9.71 on April 04, 2024, which is -43.24% below the current Price to Book Ratio (P/B).
PROCEPT BioRobotics Corporation average Price to Book Ratio (P/B) for the last 52 weeks is 14.15.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGM: PRCT

PROCEPT BioRobotics Corporation

CEO	Dr. Reza Zadno Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	900 Island Drive
Employees	626
Sector	Technology
Industries Robotics Biotechnology

Description

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

Key trends

Past 5 years